Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Medical Director
Merck Sharp & Dohme LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
188 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital São Carlos-Oncocentro Ce ( Site 0208)
Fortaleza, Ceará, Brazil
- Liga Norte Riograndense Contra O Câncer-Centro de Pesquisa Clínica ( Site 0201)
Natal, Rio Grande do Norte, Brazil
- Oncosite - Centro de Pesquisa Clinica Em Oncologia ( Site 0206)
Ijuí, Rio Grande do Sul, Brazil
- Irmandade Da Santa Casa de Misericórdia de Porto Alegre-Centro de Pesquisa Novos Tratamentos Em Cân
Porto Alegre, Rio Grande do Sul, Brazil
- Cepen - Centro de Pesquisa E Ensino Em Oncologia de Santa Catarina ( Site 0209)
Florianópolis, Santa Catarina, Brazil
- Instituto Nacional de Câncer José Alencar Gomes Da Silva - Inca ( Site 0204)
Rio de Janeiro, Brazil
- Icesp - Instituto Do Câncer Do Estado de São Paulo-Pesquisa Clinica ( Site 0200)
São Paulo, Brazil
- Núcleo de Pesquisa Clínica Da Rede São Camilo ( Site 0207)
São Paulo, Brazil
- Bc Cancer Victoria-Clinical Trials Unit ( Site 0107)
Victoria, British Columbia, Canada
- Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0104)
Hamilton, Ontario, Canada
- Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0102)
Kingston, Ontario, Canada
- Lakeridge Health ( Site 0106)
Oshawa, Ontario, Canada
- Centre Intégré de Santé Et de Services Sociaux (cisss) de la-Centre Intégré de Cancérologie de Lava
Laval, Quebec, Canada
- Cido Spa-Oncology ( Site 0707)
Temuco, Araucania, Chile
- James Lind Centro de Investigacion del Cancer ( Site 0711)
Temuco, Araucania, Chile
- Ic la Serena Research ( Site 0710)
La Serena, Coquimbo Region, Chile
- Clínica Puerto Montt ( Site 0713)
Port Montt, Los Lagos Region, Chile
- Oncocentro Valdivia ( Site 0715)
Valdivia, Los Ríos Region, Chile
- Clinica Universidad Catolica del Maule-Oncology ( Site 0703)
Talca, Maule Region, Chile
- Bradfordhill ( Site 0701)
Santiago, Region M. de Santiago, Chile
- Centro de Estudios Clínicos Saga-Cecsaga ( Site 0712)
Santiago, Region M. de Santiago, Chile
- Falp ( Site 0702)
Santiago, Region M. de Santiago, Chile
- Orlandi Oncologia ( Site 0700)
Santiago, Region M. de Santiago, Chile
- Bradford Hill Norte ( Site 0708)
Antofagasta, Chile
- Anhui Provincil Hospital South District-Respiratory Medicine Dept ( Site 2017)
Hefei, Anhui, China
- the First Affiliated Hospital of Anhui Medical University ( Site 2022)
Hefei, Anhui, China
- Beijing Cancer Hospital-Thoracic Cancer Department A ( Site 2003)
Beijing, Beijing Municipality, China
- Beijing Cancer Hospital-Intrathoratic Deparmtment Ii ( Site 2001)
Beijing, Beijing Municipality, China
- Beijing Chest Hospital,capital Medical University ( Site 2020)
Beijing, Beijing Municipality, China
- Beijing Peking Union Medical College Hospital-Pneumology Department ( Site 2009)
Beijing, Beijing Municipality, China
- Cancer Hospital Chinese Academy of Medical Science-Oncology ( Site 2030)
Beijing, Beijing Municipality, China
- Army Medical Center of People'S Liberation Army-Respiratory ( Site 2025)
Chongqing, Chongqing Municipality, China
- Chongqing Cancer Hospital-Medical Oncology ( Site 2028)
Chongqing, Chongqing Municipality, China
- Fujian Provincial Cancer Hospital-Oncology Department ( Site 2023)
Fuzhou, Fujian, China
- Fuzhou General Hospital of Nanjing Military Command-Oncology Department ( Site 2029)
Fuzhou, Fujian, China
- Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine (
Guangzhou, Guangdong, China
- Harbin Medical University Cancer Hospital ( Site 2006)
Harbin, Heilongjiang, China
- Henan Cancer Hospital ( Site 2015)
Zhengzhou, Henan, China
- Wuhan Union Hospital-Medical Oncology ( Site 2019)
Wuhan, Hubei, China
- Hunan Cancer Hospital-Thoracic Oncology Ii ( Site 2013)
Changsha, Hunan, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Apr 2021
- Primary completion
- 5 Sept 2024
- Completion
- 27 Jan 2026
- Last update posted
- 26 Jun 2026
- Registered enrollment
- 1,264
- Registry id
- NCT04738487
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.